Trial intelligence / Profile preview

SANsinCOVID-19: Hydroxychloroquine chemoprophylaxis in healthcare personnel

2020-001704-42Phase 4Terminated

Sponsor
IDIVAL
Start
May 2020
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, randomised trial in coronavirus disease 2019 (COVID-19) comparing Hydroxychloroquine prophylaxis with Placebo control (2 arms). Primary endpoint: Number of healthcare professionals with symptomatic or asymptomatic SARS-CoV-2 infection. Started May 2020; status: terminated.

02

Drugs

hydroxychloroquine
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on 2020-001704-42.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2020-001704-42.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call